Pipeline
Overview
XOMA has leveraged deep expertise in the discovery and development of human and humanized monoclonal antibodies to create a pipeline of product candidates with the potential to treat cardiovascular, infectious, inflammatory, metabolic and oncologic diseases.
Our flagship candidate, gevokizumab (XOMA 052), is a human antibody to interleukin beta (IL-1β) in clinical development with the potential to address non-infectious uveitis including Behçet’s uveitis, moderate to severe acne, cardiovascular disease and other conditions associated with inflammation. Gevokizumab has been evaluated in Phase 1 and 2 clinical trials involving approximately 500 patients. Development of gevokizumab is being conducted collaboration with Les Laboratoires Servier, a leading independent pharmaceutical company.
Our preclinical pipeline includes the XMetA and XMetS programs to develop antibodies that modulate the insulin receptor for the treatment of diabetes and metabolic syndrome, and additional programs focused on the validated oncology targets TGFβ, FGFR4 and RON.
We are also developing XOMA 3AB, a three-antibody co-formulation drug product candidate designed to treat botulinum toxin (Type A) poisoning, among the most deadly bioterror threats. XOMA 3AB, currently in Phase 1 testing, is being developed with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
We have two product candidates partnered with Novartis in our pipeline: HCD122, a monoclonal antibody to CD40 currently in Phase 1/2 clinical trials for the treatment of lymphoma, and LFA102, a monoclonal antibody to the prolactin receptor currently in a Phase 1 clinical trial for certain breast and prostate cancers..
